Navigation Links
Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Date:1/3/2013

Seattle, Washington (PRWEB) January 03, 2013

Biosim Pharmaceuticals LLC (http://www.biosimllc.com) today announced it will be participating in the Biotech Showcase 2013 on January 7th-9th. The Biotech showcase, held alongside the JP Morgan 2013 Healthcare Conference in San Francisco, brings together biopharmaceutical executives from around the world into a collaborative learning environment.

Biosim Pharmaceuticals, LLC will be scheduling private one to one meetings with partners and interested companies throughout the conference regarding Biosim's flagship product, a generic ACTHAR gel. The brand H.P. ACTHAR gel is a highly purified corticotrophin gelatin depot formulation manufactured by Questcor Pharmaceuticals for the treatment of infantile spasms, multiple sclerosis, nephrotic syndrome and rheumatic disorders. Please contact bd(at)biosimllc(dot)com to schedule a meeting.

About BioSim Pharmaceuticals:
BioSim (biosimllc.com), a Seattle-based pharmaceutical company, focuses on building a portfolio of generic drugs for the orphan disease markets. BioSim consists of a team of highly capable individuals working together to implement both the near, and long-term objectives of advancing our pre-clinical and clinical development, all the way through late-stage development.

Read the full story at http://www.prweb.com/releases/2013/1/prweb10286464.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. Daiichi Sankyo And Coherus BioSciences Establish Strategic Collaboration To Develop And Commercialize Biosimilar Candidates
2. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
3. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
4. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
5. Biosimilars: Global Markets
6. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
9. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Despite the volatility that continues to ... Today,s pre-market research on ActiveWallSt.com directs the investor community,s focus ... RDUS ), Cerus Corp. (NASDAQ: CERS ), ... Prime Therapeutics Inc. (NASDAQ: FPRX ). Register with ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/25/2016)... Bangkok, Thailand (PRWEB) , ... May 25, 2016 ... ... the participation of a Thai delegation at BIO 2016 in San Francisco. Located ... private sector will be available to answer questions and discuss the Thai biotechnology ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... WEDI, the ... information exchange, today announced that Charles W. Stellar has been named by the WEDI ... CEO since January 2016. As an executive leader with more than 35 years of ...
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth ... held The Future of San Diego Life Science event at the Estancia La Jolla ... attended the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):